| 1 |
34287884 | Retraction. | 2022 Mar |
1 |
| 2 |
35169858 | Inhibition of the VEGF signaling pathway attenuates tumor‑associated macrophage activity in liver cancer. | 2022 Apr |
2 |
| 3 |
35434034 | Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer. | 2022 Mar |
1 |
| 4 |
33861751 | CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells. | 2021 |
5 |
| 5 |
34619972 | Tumor-associated macrophages increase COX-2 expression promoting endocrine resistance in breast cancer via the PI3K/Akt/mTOR pathway. | 2021 Sep |
1 |
| 6 |
31604073 | Knockdown of PTEN decreases expression of estrogen receptor β and tamoxifen sensitivity of human breast cancer cells. | 2020 Jan |
1 |
| 7 |
31710162 | Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. | 2020 Jan |
1 |
| 8 |
32521278 | Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR Cascade. | 2020 Jun 9 |
1 |
| 9 |
32668964 | MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant Breast Cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway. | 2020 |
1 |
| 10 |
32825760 | Metformin Restores the Drug Sensitivity of MCF-7 Cells Resistant Derivates via the Cooperative Modulation of Growth and Apoptotic-Related Pathways. | 2020 Aug 21 |
1 |
| 11 |
32921987 | Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer. | 2020 |
3 |
| 12 |
30145819 | Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway. | 2019 Feb |
5 |
| 13 |
30304547 | Tamoxifen ameliorates obstructive nephropathy through Src and the PI3K/Akt/mTOR pathway. | 2019 Jan |
6 |
| 14 |
30542717 | Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression. | 2019 Jan |
3 |
| 15 |
30747221 | Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway. | 2019 Mar |
1 |
| 16 |
31088266 | Colon Cancer Cell Secretes EGF to Promote M2 Polarization of TAM Through EGFR/PI3K/AKT/mTOR Pathway. | 2019 Jan 1 |
1 |
| 17 |
31195027 | Phospho-mTOR expression in human glioblastoma microglia-macrophage cells. | 2019 Oct |
1 |
| 18 |
31519767 | Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells. | 2019 Nov |
2 |
| 19 |
31657150 | Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. | 2019 Dec |
1 |
| 20 |
29345254 | The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8. | 2018 Aug |
1 |
| 21 |
29934412 | Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. | 2018 Aug |
1 |
| 22 |
30154572 | Investigation of Novel Regulation of N-myristoyltransferase by Mammalian Target of Rapamycin in Breast Cancer Cells. | 2018 Aug 28 |
2 |
| 23 |
28231748 | Aloe-Emodin Enhances Tamoxifen Cytotoxicity by Suppressing Ras/ERK and PI3K/mTOR in Breast Cancer Cells. | 2017 |
3 |
| 24 |
28675785 | GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance. | 2017 Oct |
1 |
| 25 |
29269484 | Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming. | 2017 Nov 15 |
3 |
| 26 |
27020861 | AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment. | 2016 Jun 1 |
1 |
| 27 |
27027343 | Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells. | 2016 May 3 |
1 |
| 28 |
27425661 | mTOR inhibitors for management of encapsulating peritoneal sclerosis: a review of literatures. | 2016 Nov |
1 |
| 29 |
27526942 | CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK/mTOR pathway. | 2016 Aug 15 |
3 |
| 30 |
27765938 | Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway. | 2016 Oct 21 |
2 |
| 31 |
25361980 | Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. | 2015 Jan |
1 |
| 32 |
25799952 | Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism. | 2015 Jun 28 |
3 |
| 33 |
25882671 | Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion. | 2015 |
1 |
| 34 |
25972244 | S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts. | 2015 Jun |
2 |
| 35 |
26158266 | Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells. | 2015 |
1 |
| 36 |
26208432 | mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. | 2015 Oct 10 |
6 |
| 37 |
26436206 | Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ERα reducing AKT/mTOR pathway. | 2015 Nov 13 |
1 |
| 38 |
24519842 | m-TOR inhibitors may be useful in the treatment of encapsulating peritoneal sclerosis (EPS). | 2014 Oct |
2 |
| 39 |
24612549 | Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. | 2014 Mar 11 |
1 |
| 40 |
25108739 | Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. | 2014 Sep |
1 |
| 41 |
23242584 | Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. | 2013 Jan |
6 |
| 42 |
23299092 | Advances in the treatment of luminal breast cancer. | 2013 Feb |
1 |
| 43 |
23799775 | Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities. | 2013 Jul 25 |
1 |
| 44 |
23814023 | Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. | 2013 Oct |
1 |
| 45 |
23844917 | Endocrine therapy: is the first generation of targeted drugs the last? | 2013 Aug |
1 |
| 46 |
23991038 | Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling. | 2013 |
1 |
| 47 |
23999849 | Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. | 2013 Sep 27 |
2 |
| 48 |
24131622 | The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. | 2013 |
1 |
| 49 |
22835717 | Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. | 2012 Nov |
2 |
| 50 |
22922893 | Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. | 2012 Nov |
1 |